Evidence map›Paper›PMID 31494742›Full record

ArticleCancer immunology, immunotherapy : CII2019

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.

Benoit Milcent, Nathalie Josseaume, Quentin Riller, Ilenia Giglioli, Emilia Rabia, Claire Deligne, Jean-Baptiste Latouche, Mohamad Hamieh, Alexandre Couture, Olivier Toutirais and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Benoit MilcentSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.
Nathalie JosseaumeSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.
Quentin RillerSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.
Ilenia GiglioliSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.
Emilia RabiaSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.
Claire DeligneSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.
Jean-Baptiste LatoucheInserm U1245, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, Rouen University Hospital, Rouen, France.
Mohamad HamiehInserm U1245, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, Rouen University Hospital, Rouen, France.
Alexandre CoutureInserm U1245, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, Rouen University Hospital, Rouen, France.
Olivier ToutiraisUnicaen, Inserm 1237, Physiopathology and Imaging of Neurological Disorders, Normandie University, Caen, France.
Yu-Chun LoneInserm U1014, Hôpital Paul Brousse, Villejuif, France.
Raphaël Jeger-MadiotInserm U1135, CNRS ERL8255, Center for Immunology and Microbial Infection, Paris, France.
Stéphanie Graff-DuboisInserm U1135, CNRS ERL8255, Center for Immunology and Microbial Infection, Paris, France.
Sandy AmorimAPHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Sorbonne Paris Cité, Paris, France.
Pascale LoiseauLaboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.
Antoine ToubertLaboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.
Pauline BriceAPHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Sorbonne Paris Cité, Paris, France.
Catherine ThieblemontAPHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Sorbonne Paris Cité, Paris, France.
Jean-Luc TeillaudSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France.
Sophie SibérilSorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Inserm UMRS 1138, "Cancer, Immune Control and Escape" Laboratory, Centre de Recherche des Cordeliers, Paris, France. sophie.siberil@upmc.fr.ORCID http://orcid.org/0000-0003-0184-2886
Délégation Paris 5 · FRInserm · FRCentre National de la Recherche Scientifique · FRDélégation Paris 7 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preclinical and clinical studies have suggested that cancer treatment with antitumor antibodies induces a specific adaptive T cell response. A central role in this process has been attributed to CD4

Indexed as

AnimalsAntigens, CD20CD4-Positive T-LymphocytesFemaleHLA-DRB1 ChainsHumansInterferon-gammaLymphomaMiceRituximabAntigens, CD20HLA-DRB1 ChainsInterferon-gammaRituximabCD4+ T cell responsesFollicular lymphomaHuman CD20-derived peptidesNon-mutated self-peptides

Identifiers

PMID31494742
PMCPMC6805815
OpenAlexW2971890465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.